IQVIA (IQV)
(Delayed Data from NYSE)
$225.36 USD
-4.48 (-1.95%)
Updated Oct 7, 2024 04:00 PM ET
After-Market: $225.35 -0.01 (0.00%) 7:16 PM ET
3-Hold of 5 3
B Value C Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$225.36 USD
-4.48 (-1.95%)
Updated Oct 7, 2024 04:00 PM ET
After-Market: $225.35 -0.01 (0.00%) 7:16 PM ET
3-Hold of 5 3
B Value C Growth C Momentum C VGM
Zacks News
CRA International (CRAI) to Post Q4 Earnings: What to Expect?
by Zacks Equity Research
CRA International's (CRAI) fourth-quarter 2023 revenues are likely to have benefitted from improved Forensic Services and Life Sciences performances.
FTI Consulting (FCN) Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
FTI Consulting's (FCN) top line benefits from a strong segmental performance in the fourth quarter of 2023.
IQVIA Holdings (IQV) Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
IQVIA Holdings' (IQV) revenues increase year over year in fourth-quarter 2023.
Compared to Estimates, IQVIA (IQV) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for IQVIA (IQV) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
IQVIA Holdings (IQV) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
IQVIA (IQV) delivered earnings and revenue surprises of 0.71% and 2.17%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
IQVIA (IQV) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
IQVIA's (IQV) revenues are likely to increase year over year on the back of improving segmental performance.
Stay Ahead of the Game With IQVIA (IQV) Q4 Earnings: Wall Street's Insights on Key Metrics
by Zacks Equity Research
Evaluate the expected performance of IQVIA (IQV) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Zacks.com featured highlights include NRG Energy, Darden Restaurants, Allison Transmission Holdings and IQVIA Holdings
by Zacks Equity Research
NRG Energy, Darden Restaurants, Allison Transmission Holdings and IQVIA Holdings are part of the Zacks Screen of the Week article.
IQV or IDXX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
IQV vs. IDXX: Which Stock Is the Better Value Option?
4 GARP Stocks to Scoop up for Maximum Returns
by Zacks Equity Research
Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. NRG, DRI, ALSN and IQV are some stocks that hold promise.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Here's Why You Should Invest in IQVIA Holdings (IQV) Now
by Zacks Equity Research
IQVIA's (IQV) combined offerings of research and development and commercial services help it to develop trusted relationships.
IQVIA (IQV) Climbs 17% in 3 Months: Here's What to Know
by Zacks Equity Research
IQVIA (IQV) benefits from revenue growth and disciplined cost management.
IQVIA (IQV) Stock Gains 8% in a Month: Here's What to Know
by Zacks Equity Research
IQVIA (IQV) aims at market expansion through innovation and service improvements.
Why Is IQVIA (IQV) Up 12.4% Since Last Earnings Report?
by Zacks Equity Research
IQVIA (IQV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
IQVIA (IQV) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for IQVIA (IQV) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
IQVIA Holdings (IQV) Q3 Earnings Top Estimates, Revenues Miss
by Zacks Equity Research
IQVIA Holdings' (IQV) revenues increase year over year in third-quarter 2023.
IQVIA Holdings (IQV) Q3 Earnings Surpass Estimates
by Zacks Equity Research
IQVIA (IQV) delivered earnings and revenue surprises of 1.22% and 1.21%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Shockwave Medical (SWAV) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Shockwave Medical (SWAV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why IQVIA (IQV) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
IQVIA (IQV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
IQVIA (IQV) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
IQVIA's (IQV) revenues are likely to increase year over year on the back of improving segmental performance.
IQVIA Holdings (IQV) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
IQVIA (IQV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for West Pharmaceutical (WST) in Q3 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) third-quarter 2023 results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.
4 Medical Product Stocks Set to Outpace Q3 Earnings Estimates
by Indrajit Bandyopadhyay
Medical Product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EW, PODD, DXCM and IQV are poised ahead of their earnings release.